What is the recommended initial treatment regimen for a newly diagnosed multiple myeloma patient, including options for transplant‑eligible and transplant‑ineligible individuals?

Initial Treatment for Newly Diagnosed Multiple Myeloma

For transplant-eligible patients, quadruplet induction therapy with daratumumab plus bortezomib/lenalidomide/dexamethasone (Dara-VRd) should be the preferred regimen, followed by autologous stem cell transplantation and lenalidomide maintenance. For transplant-ineligible patients, daratumumab/lenalidomide/dexamethasone (DaraRd) continued until progression is the standard of care 1, 2, 3, 4.

Transplant-Eligible Patients

Induction Therapy

Preferred regimen: Daratumumab/Bortezomib/Lenalidomide/Dexamethasone (Dara-VRd) - This quadruplet represents the current standard based on the most recent ASCO guidelines 4. The addition of daratumumab to the VRd backbone provides deeper responses and improved progression-free survival.

Alternative preferred option: Bortezomib/Lenalidomide/Dexamethasone (VRd) - This remains a Category 1 recommendation with strong long-term data showing median PFS of 41 months versus 29 months for lenalidomide/dexamethasone alone, and median OS of 84 months 1. The ENDURANCE trial confirmed VRd's efficacy with median PFS of 34.4 months 1.

Other acceptable options:

• Bortezomib/Cyclophosphamide/Dexamethasone (CyBorD) - Particularly valuable for patients with acute renal insufficiency, with ORR of 88% and 5-year PFS of 42% 1. Consider switching to VRd after renal function improves.
• Carfilzomib/Lenalidomide/Dexamethasone (KRd) - Shows 74% VGPR rate but carries more cardiac, pulmonary, and renal toxicity compared to VRd 1

Critical Management Points

Avoid myelotoxic agents (alkylating agents, nitrosoureas, prolonged lenalidomide exposure) before stem cell harvest to preserve stem cell reserve 5.

Administer 4-6 cycles of induction before proceeding to stem cell collection 1.

Use triplet regimens as standard; doublet regimens are reserved only for elderly or frail patients 5.

Consolidation and Maintenance

Autologous stem cell transplantation remains standard of care (Category 1) for medically fit patients 6.

Lenalidomide maintenance (Category 1) should be continued until progression, as it significantly improves both PFS and OS 5, 6. Consider adding daratumumab to maintenance based on emerging data 4.

Important caveat: Discuss increased risk of secondary malignancies with lenalidomide maintenance, though benefits typically outweigh risks 5.

Transplant-Ineligible Patients

First-Line Therapy

Preferred regimen: Daratumumab/Lenalidomide/Dexamethasone (DaraRd) continued until progression - The MAIA trial demonstrated this as superior with 30-month PFS of 70.6% versus 55.6% for Rd alone (HR 0.56, P<0.001) 1, 2, 3. This is now FDA-approved and represents the current standard.

Alternative preferred options:

• Daratumumab/Bortezomib/Melphalan/Prednisone (Dara-VMP) - Category 1 based on ALCYONE trial showing median PFS of 36.4 versus 19.3 months (HR 0.60, P=0.0003) 1, 3. However, melphalan-containing regimens are rarely used in North America.
• Bortezomib/Lenalidomide/Dexamethasone (VRd) - EMA-approved in 2019 showing superior PFS (41 vs 29 months) and OS benefit 3

Other acceptable regimens:

• Carfilzomib/Lenalidomide/Dexamethasone - Effective across all age groups (oldest patient 88 years) with 30.5-month PFS of 79.6% 1
• Ixazomib/Lenalidomide/Dexamethasone - All-oral option with similar efficacy in older patients 1
• Bortezomib/Dexamethasone - Useful for frail/elderly patients as doublet therapy 1

Treatment Duration

Continue therapy until disease progression based on FIRST trial data showing continuous lenalidomide/dexamethasone reduced progression risk by 28% versus fixed-duration therapy 1.

Essential Supportive Care

Thromboprophylaxis: Full-dose aspirin required with immunomodulator-based therapy; therapeutic anticoagulation for high-risk patients 5, 1.

Herpes zoster prophylaxis: Mandatory for all patients receiving proteasome inhibitors 5.

Bortezomib administration: Use subcutaneous route (preferred) for patients with pre-existing or high-risk peripheral neuropathy 5.

Common Pitfalls to Avoid

• Do not use melphalan-containing regimens in transplant-eligible patients before stem cell collection
• Do not delay stem cell harvest in patients receiving prolonged lenalidomide therapy
• Do not use high-dose dexamethasone in elderly patients (>65 years) - inferior survival outcomes 1
• Do not omit thromboprophylaxis with immunomodulator combinations - significantly increases VTE risk